Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pneumococcal vaccine.

L G Rubin1

  • 1Department of Pediatrics, Schneider Children's Hospital of North Shore-Long Island Jewish Health System, New Hyde Park, New York, USA. lrubin@lij.edu

Pediatric Clinics of North America
|April 13, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vancomycin and ceftazidime bioactivities persist for at least 2 weeks in the lumen in ports: simplifying treatment of port-associated bloodstream infections by using the antibiotic lock technique.

Antimicrobial agents and chemotherapy·2001
Same author

Apparent false positive detection of group a Streptococcus antigen resulting from pharyngeal infection with a nonhemolytic Streptococcus pyogenes.

The Pediatric infectious disease journal·2000
Same author

Childhood immunizations 2000. Introduction.

Pediatric clinics of North America·2000
Same author

Cutaneous neonatal herpes simplex infection associated with ritual circumcision.

The Pediatric infectious disease journal·2000
Same author

Cure of implantable venous port-associated bloodstream infections in pediatric hematology-oncology patients without catheter removal.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1999
Same author

Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports).

Antimicrobial agents and chemotherapy·1999
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

New pneumococcal conjugate vaccines show promise in preventing serious infections like pneumonia and meningitis in infants. These vaccines, targeting Streptococcus pneumoniae, offer improved efficacy over older versions for young children.

Area of Science:

  • * Infectious Diseases
  • * Vaccinology
  • * Microbiology

Background:

  • * Streptococcus pneumoniae (pneumococcus) is a leading cause of severe infections, including meningitis and pneumonia.
  • * The bacterial polysaccharide capsule is a key virulence factor, with over 90 identified serotypes.
  • * Existing polysaccharide vaccines have limited effectiveness in infants and young children.

Purpose of the Study:

  • * To evaluate the efficacy of a novel heptavalent pneumococcal conjugate vaccine in infants.
  • * To assess the vaccine's ability to prevent invasive pneumococcal infections, pneumonia, and acute otitis media.

Main Methods:

  • * Randomized, double-blind, placebo-controlled studies.
  • * Administration of a heptavalent pneumococcal conjugate vaccine in a series of doses to infants.

Related Experiment Videos

  • * Monitoring for vaccine-preventable pneumococcal disease outcomes.

    • Main Results:

    • * The heptavalent pneumococcal conjugate vaccine demonstrated efficacy in preventing invasive infections caused by vaccine serotypes.
    • * Significant reduction in episodes of lobar pneumonia attributed to vaccine serotypes.
    • * Effective prevention of acute otitis media caused by the targeted pneumococcal serotypes.

    Conclusions:

    • * Pneumococcal conjugate vaccines represent a significant advancement in protecting infants against pneumococcal diseases.
    • * The heptavalent vaccine is efficacious in preventing invasive pneumococcal infections, pneumonia, and otitis media in infants.
    • * Conjugate vaccines overcome the limitations of polysaccharide vaccines in young populations.